Per Grufman

Per Grufman Email and Phone Number

Chief Executive Officer @ Biocrucible
Stockholm County, Sweden
Per Grufman's Location
Saffron Walden, England, United Kingdom, United Kingdom
About Per Grufman

CEO and VP of Research and Development with a demonstrated history of working in the medical device industry. Experience from most aspects of medical devices and diagnostics. Skilled in Medical Devices, Diagnostics, , Molecular Biology, Biotechnology, Research and Development and crossfunctional leadership. Strong research professional with a PhD focused in Immunology from Karolinska institutet.Lives in Cambridge, UK and also have an apartment in Stockholm, Sweden.Any views or comments that I express are my own and does not reflect the views of my employer

Per Grufman's Current Company Details
Biocrucible

Biocrucible

View
Chief Executive Officer
Stockholm County, Sweden
Per Grufman Work Experience Details
  • Biocrucible
    Chief Executive Officer
    Biocrucible
    Stockholm County, Sweden
  • Self-Employed
    Consultant And Advisor To Biotech Companies
    Self-Employed Dec 2024 - Present
    Consultant and Advisor working with biotech companies in Europe. Currently supporting a German molecular diagnostic company as well as a French medical device company. Providing expertise in product development, investor relations, business development etc.
  • Leopard Biosciences
    Cxo
    Leopard Biosciences Dec 2024 - Present
    Munich, De
    Leopard Biosciences develops molecular diagnostics aiming primarily on the point of care market. The company has developed a unique technology based on CRISPR.
  • Biocrucible
    Chief Executive Officer
    Biocrucible Jan 2023 - Dec 2024
    Cambridge, Gb
    Biocrucible is a part of the Sapphiros group and are developing molecular and lateral flow diagnostics. The company has almost 80 staff that are based across two locations in Cambridge. For molecular diagnostics we utilise the unique molten RPA technology that allows us to develop and manufacture very low cost instrument free molecular diagnostics.
  • Lumiradx
    Vp Of R&D
    Lumiradx Jun 2021 - Dec 2022
    London, London, Gb
    Responsibility includes responsibility for POC V&V, Product Life cycle management including investigations as well as product development for molecular assays on the LumiraDx point of care platform.
  • Cepheid Ab
    Executive Director Research And Development, Sweden
    Cepheid Ab Apr 2015 - May 2021
    Solna, Stockholm, Se
    Cepheid is providing molecular diagnostics assays in all parts of the world. The main strengths of the platform is the ease of use and ability to operate in all types of environments. The R&D team in Sweden consist of 50+ associates focused on developing assays for the GeneXpert platform. The team has developed multiple assays for infectious diseases including work on viruses, bacteria and parasites. I am also responsible for our R&D activities in China.Cepheid is fully owned by Danaher corporation and the use of the Danaher Business System is helping to drive improvements throughout the organization.
  • Cepheid
    Senior Director Research And Development, Sweden
    Cepheid Jun 2010 - Apr 2015
    Sunnyvale, Ca, Us
    Cepheid is developing and marketing molecular diagnostic products based on real time PCR. Responsibilities include Research strategy and guidance of staff.
  • Absorber Ab
    Vp, Head Of Research And Development
    Absorber Ab Jul 2004 - Jun 2010
    Stockholm, Se
    AbSorber is developing and selling products for the organ transplantation market.Responsibility included Research strategy and guidance of scientific staff, research collaborations, intellectual property issues, Clinical studies, Regulatory affairs etc. I was responsible for the development of the first product the company developed which was used to improve prediction of rejection of transplants. As head of R&D I also participated in meetings with the board of directors as well as meetings with investors and other external partners. Responsibilities also included setting up manufacturing and QC of the companys first product at the site of an external partner.I joined the company as the first employee except for the founders and during my time with AbSorber it grow to become 10+ staff although most of the organization remained virtual and the majority of work including R&D was performed through external collaborations.
  • Accuro Immunology Ab
    Vp Murine Research
    Accuro Immunology Ab May 2003 - Jun 2004
    Accuro Immunology AB was developing therapeutic cancer vaccines. The first product which was a cell based vaccine was ready to go into safety and toxicity studies. Responsibilities included animal models (mice) and molecular biology, guidance and training of scientific staff working within these areas, work with intellectual property issues, research strategy, financing etc. I was also responsible for reports and presentations to the board and potential investors
  • Accuro Immunology Ab
    Team Leader Murine Research
    Accuro Immunology Ab Jun 2000 - Apr 2003

Per Grufman Education Details

  • Karolinska Institutet
    Karolinska Institutet
    Immunology
  • Stockholm University
    Stockholm University
    Biology

Frequently Asked Questions about Per Grufman

What company does Per Grufman work for?

Per Grufman works for Biocrucible

What is Per Grufman's role at the current company?

Per Grufman's current role is Chief Executive Officer.

What schools did Per Grufman attend?

Per Grufman attended Karolinska Institutet, Stockholm University.

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Download 750 million emails and 100 million phone numbers

Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.